On this page
MODY3 (HNF1A diabetes)
MODY3 is a genetic type of diabetes that usually appears in adolescence or early adulthood. It accounts for a small but significant percentage of all diabetes cases and is caused by pathogenic variants in the HNF1A gene, impacting blood sugar control.
Overview
MODY3, also known as HNF1A diabetes, is a specific type of diabetes that is inherited. Unlike type 1 or type 2 diabetes, MODY3 is caused by a change in a single gene, HNF1A, which leads to problems with how the body produces insulin [PMID:33678438]. Insulin is a hormone essential for controlling blood sugar levels.
This condition typically develops in adolescence or early adulthood, often before the age of 25. It shares some features with both type 1 and type 2 diabetes, which can sometimes lead to an initial misdiagnosis. However, understanding the genetic cause is crucial for correct diagnosis and management, as the treatment approaches for MODY3 can differ significantly from other forms of diabetes.
MODY3 is estimated to account for 1-2% of all diabetes cases. Recognising MODY3 is important because individuals with this condition often respond well to specific types of diabetes medication, particularly sulphonylureas, and may not require insulin injections initially [PMID:30691516].
Symptoms & clinical features
The symptoms of MODY3 are similar to those of other types of diabetes, often developing gradually. Common symptoms include increased thirst (polydipsia), frequent urination (polyuria), unexplained weight loss, and fatigue. These symptoms arise because the body cannot effectively use glucose (sugar) from food, leading to high blood sugar levels.
In some individuals, MODY3 may be discovered incidentally during routine blood tests that show elevated blood sugar levels, even before noticeable symptoms appear. The onset is typically in the teenage years or early adulthood, but it can occur earlier or later. While the disease progresses, insulin production by the pancreas gradually declines, which can lead to higher blood sugar levels over time.
Compared to type 1 diabetes, individuals with MODY3 generally do not experience a sudden, severe onset of symptoms or ketoacidosis (a serious complication) at diagnosis. However, complications associated with long-term high blood sugar, such as kidney problems, eye damage, and nerve damage, can still occur if MODY3 is not well-managed, similar to other forms of diabetes.
Video: Genetics 101
Affected organs
MODY3 primarily affects the pancreas, specifically the beta cells within the islets of Langerhans. These beta cells are responsible for producing and releasing insulin, which is vital for regulating blood glucose levels. In individuals with MODY3, the HNF1A gene changes impair the normal function of these pancreatic beta cells, leading to a reduced ability to secrete insulin [PMID:33678438].
Over time, this reduced insulin secretion leads to persistently high blood sugar levels. While the pancreas is the primary organ directly affected in terms of insulin production, sustained high blood sugar can impact many other organ systems throughout the body if not controlled. This can include the eyes (potentially leading to retinopathy), kidneys (nephropathy), nerves (neuropathy), and the cardiovascular system, increasing the risk of heart disease and stroke.
Risks & severity
The severity of MODY3 can vary among individuals, even within the same family. Typically, the condition presents in adolescence or early adulthood, often before the age of 25. However, the age of onset can range from childhood to later adulthood. The disease is generally progressive, meaning that the ability of the pancreas to produce insulin tends to decrease over time, leading to worsening blood sugar control if untreated.
Individuals with MODY3 have an increased risk of developing typical diabetes complications due to prolonged high blood sugar. These complications can include damage to the small blood vessels in the eyes (diabetic retinopathy), kidneys (diabetic nephropathy), and nerves (diabetic neuropathy). There is also an increased risk of cardiovascular disease, such as heart attacks and strokes. However, with appropriate management and good blood sugar control, the risk and severity of these complications can be significantly reduced.
Genetic causes
MODY3 is caused by pathogenic variants in the HNF1A gene. This gene provides instructions for making a protein called hepatocyte nuclear factor 1-alpha (HNF-1α). HNF-1α is a transcription factor, meaning it plays a crucial role in controlling the activity of other genes.
Specifically, HNF-1α is vital for the proper development and function of pancreatic beta cells, the cells responsible for producing insulin. It regulates the expression of genes involved in insulin production, glucose transport, and overall beta cell function [PMID:33678438].
When a pathogenic variant occurs in the HNF1A gene, the HNF-1α protein may be non-functional, partially functional, or produced in insufficient amounts. This disruption impairs the ability of pancreatic beta cells to produce and release enough insulin in response to blood glucose levels, leading to high blood sugar and the symptoms of diabetes.
- HNF1A HNF1 homeobox AThe HNF1A gene encodes a protein that acts as a transcription factor, playing a crucial role in the development and function of pancreatic beta cells and liver, influencing blood sugar regulation.
Inheritance pattern
MODY3 is inherited in an autosomal dominant pattern. This means that only one copy of the altered HNF1A gene in each cell is enough to cause the condition. Autosomal dominant inheritance means that the gene is located on a non-sex chromosome (autosome) and that a single copy of the altered gene is sufficient to cause the condition.
If a parent has MODY3, there is a 50% (1 in 2) chance with each pregnancy that their child will inherit the altered gene and develop the condition. This applies to both male and female children equally. Individuals with MODY3 may have inherited the pathogenic variant from one of their parents, or it can sometimes arise as a new genetic change in the affected individual (a de novo variant), although this is less common for MODY3.
Family members of an individual diagnosed with MODY3, particularly first-degree relatives (parents, siblings, children), may be offered genetic counselling and testing to determine if they also carry the HNF1A variant, even if they do not yet have symptoms.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosing MODY3 typically involves a combination of clinical assessment and genetic testing. Clinical suspicion often arises when diabetes is diagnosed in a young person (under 25 years old) who does not fit the typical profile for type 1 or type 2 diabetes, especially if there is a family history of diabetes affecting multiple generations in an autosomal dominant pattern.
Initial diagnostic steps might include blood tests to measure blood glucose levels, glycated haemoglobin (HbA1c), and sometimes C-peptide levels, which can indicate the body's own insulin production. Genetic testing for variants in the HNF1A gene is the definitive way to confirm a diagnosis of MODY3. This testing usually involves DNA sequencing to identify specific pathogenic variants in the gene. In the UK, genetic testing for monogenic diabetes is available through the NHS Genomic Medicine Service (GMS), often initiated by referral from a diabetes specialist or general practitioner to a clinical genetics service. This falls under specific R-codes for monogenic diabetes testing, such as R183 Monogenic diabetes.
Management & lifestyle
The management of MODY3 is distinct from other forms of diabetes. Many individuals with MODY3 respond very well to low-dose sulphonylurea medications, which help the pancreas release more insulin [PMID:30691516]. This is a key difference from type 1 diabetes, where insulin injections are always required, and from many cases of type 2 diabetes, where sulphonylureas may not be the first-line treatment.
Over time, as insulin production may further decline, some individuals with MODY3 may eventually require insulin therapy. Regular monitoring of blood glucose levels and HbA1c is essential to assess treatment effectiveness and adjust medication as needed. A healthy lifestyle, including a balanced diet and regular physical activity, is also an important part of managing blood sugar levels and overall health.
Ongoing care usually involves a multidisciplinary team, including an endocrinologist or diabetes specialist, a diabetes nurse educator, and sometimes a dietitian. Regular screening for long-term complications of diabetes, such as eye and kidney problems, is also part of routine management, allowing for early detection and intervention if issues arise.
UK care pathway
In the UK, individuals suspected of having MODY3 are typically referred to a diabetes specialist, who may then refer them to a clinical genetics service. This pathway ensures access to specialist assessment and genetic testing. The NHS Genomic Medicine Service (GMS) provides comprehensive genomic testing, with specific R-codes such as R183 (Monogenic diabetes) guiding the diagnostic process.
If a diagnosis of MODY3 is confirmed, individuals will receive ongoing care through NHS diabetes clinics, often overseen by an endocrinologist. Genetic counsellors play a vital role in explaining the genetic basis of MODY3, its inheritance pattern, and the implications for family members. They can also facilitate cascade testing for at-risk relatives who may wish to know their genetic status.
Frequently asked questions
What is the main difference between MODY3 and type 1 or type 2 diabetes?
The main difference is the cause. MODY3 is caused by a change in a single gene, HNF1A, which directly affects insulin production. Type 1 diabetes is an autoimmune condition, and type 2 diabetes is typically multifactorial, involving both genetic and lifestyle factors.
If I have MODY3, will my children also have it?
MODY3 is inherited in an autosomal dominant pattern. This means if you have MODY3, each of your children has a 50% chance of inheriting the altered HNF1A gene and developing the condition.
How is MODY3 usually treated?
Many individuals with MODY3 respond very well to low doses of sulphonylurea medications, which help the pancreas release more insulin. Lifestyle adjustments like diet and exercise are also important, and some individuals may eventually need insulin injections.
Can MODY3 be prevented?
No, MODY3 is a genetic condition caused by an inherited gene change, so it cannot be prevented. However, early diagnosis and appropriate management can help prevent or delay diabetes-related complications.
Who should be tested for MODY3?
Genetic testing for MODY3 is typically considered for individuals diagnosed with diabetes before age 25, especially if they have a family history of diabetes that doesn't fit typical type 1 or type 2 patterns, or if they have certain clinical features suggesting monogenic diabetes.